Osivax and GC Biopharma revealed a strategic collaboration focused on developing a new-generation influenza vaccine. The vaccine aims to combine OVX836 and GC FLU. Osivax gained those rights to advance a combination shot.
Older adults face four vaccine decisions this fall, while the federal immunization calendar still carries a 2025 date. Flu and pneumonia deaths have declined for 25 years, but one American age group saw an increase.